Evidence map›Paper›PMID 33051218›Full record

ArticleBMJ open respiratory research2020

Clinical and financial burden of hospitalised community-acquired pneumonia in patients with selected underlying comorbidities in England.

James Campling, Dylan Jones, James Chalmers, Qin Jiang, Andrew Vyse, Harish Madhava, Gillian Ellsbury, Adrian Rabe, Mary Slack

Open access · goldAbstract read
In one paragraph

Article in BMJ open respiratory research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

James CamplingVaccines Medical Affairs, Pfizer Ltd, Tadworth, UK james.campling@pfizer.com.
Dylan JonesVaccines Health Economics and Outcomes Research, Pfizer Ltd, Tadworth, UK.
James ChalmersUniversity of Dundee School of Medicine, Dundee, UK.
Qin JiangPfizer Vaccines, Collegeville, PA, USA.
Andrew VyseVaccines Medical Affairs, Pfizer Ltd, Tadworth, UK.
Harish MadhavaVaccines Medical Affairs, Pfizer Ltd, Tadworth, UK.
Gillian EllsburyVaccines Medical Affairs, Pfizer Ltd, Tadworth, UK.
Adrian RabeEpidemiology and Data Science, Health iQ Ltd, London, UK.
Mary SlackSchool of Medicine, Griffith University Faculty of Health, Gold Coast, Queensland, Australia.
Pfizer (United Kingdom) · GBGriffith University · AUHealth Economics and Outcomes Research (United Kingdom) · GBPfizer (United States) · USUniversity of Dundee · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHospitalised pneumonia may have long-term clinical and financial impact in adult patients with underlying comorbidities.

methodsWe conducted a retrospective cohort study using the Hospital Episode Statistics (HES) database to determine the clinical and financial burden over 3 years of hospitalised community-acquired pneumonia (CAP) to England's National Health Service (NHS). Subjects were adults with six underlying comorbidities (chronic heart disease (CHD); chronic kidney disease (CKD); chronic liver disease (CLD); chronic respiratory disease (CRD); diabetes mellitus (DM) and post bone marrow transplant (post-BMT)) with an inpatient admission in 2012/2013. Patients with CAP in 2013/2014 were followed for 3 years and compared with similarly aged, propensity score-matched adults with the same comorbidity without CAP.

findingsThe RR of hospital admissions increased after CAP, ranging from 1.08 (95% CI 1.04 to 1.12) for CKD to 1.38 (95% CI 1.35 to 1.40) for CRD. This increase was maintained for at least 2 years. Mean difference in hospital healthcare costs (£) was higher for CAP patients in 2013/2014; ranging from £1115 for DM to £8444 for BMT, and remained higher for 4/6 groups for 2 more years, ranging from £1907 (95% CI £1573 to £2240) for DM to £11 167 (95% CI £10 847 to £11 486) for CRD.) The OR for mortality was significantly higher for at least 3 years after CAP, ranging from 4.76 (95% CI 4.12 to 5.51, p<0.0001) for CLD to 7.50 (95%CI 4.71 to 11.92, p<0.0001) for BMT.

interpretationFor patients with selected underlying comorbidities, healthcare utilisation, costs and mortality increase for at least 3 years after being hospitalised CAP.

Indexed as

PneumoniaState MedicineAdultAgedComorbidityEnglandHumansRetrospective Studiespneumoniarespiratory infection

Identifiers

PMID33051218
PMCPMC7555110
OpenAlexW3091943720

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.